BRPI0416390A - combinações para o tratamento de doenças proliferativas - Google Patents

combinações para o tratamento de doenças proliferativas

Info

Publication number
BRPI0416390A
BRPI0416390A BRPI0416390-7A BRPI0416390A BRPI0416390A BR PI0416390 A BRPI0416390 A BR PI0416390A BR PI0416390 A BRPI0416390 A BR PI0416390A BR PI0416390 A BRPI0416390 A BR PI0416390A
Authority
BR
Brazil
Prior art keywords
proliferative diseases
combinations
treating proliferative
treatment
relates
Prior art date
Application number
BRPI0416390-7A
Other languages
English (en)
Inventor
James M Nichols
Margaret S Lee
Curtis Keith
Yanzhen Zhang
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0416390A publication Critical patent/BRPI0416390A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"COMBINAçõES PARA O TRATAMENTO DE DOENçAS PROLIFERATIVAS". A presente invenção refere-se às combinações de fármacos para o tratamento de doenças proliferativas (por exemplo, câncer). A invenção também refere-se aos métodos para identificação de novas terapias de combinação para o tratamento do câncer e outras doenças proliferativas.
BRPI0416390-7A 2003-11-12 2004-11-09 combinações para o tratamento de doenças proliferativas BRPI0416390A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
PCT/US2004/037527 WO2005046607A2 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI0416390A true BRPI0416390A (pt) 2007-02-21

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416390-7A BRPI0416390A (pt) 2003-11-12 2004-11-09 combinações para o tratamento de doenças proliferativas

Country Status (13)

Country Link
EP (1) EP1689352A2 (pt)
JP (1) JP2007524657A (pt)
KR (1) KR20060118514A (pt)
AR (1) AR046841A1 (pt)
AU (1) AU2004289311A1 (pt)
BR (1) BRPI0416390A (pt)
CA (1) CA2545423A1 (pt)
IL (1) IL175611A0 (pt)
IS (1) IS8496A (pt)
NO (1) NO20062358L (pt)
RU (1) RU2006120491A (pt)
TW (1) TW200526777A (pt)
WO (1) WO2005046607A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
TW200526777A (en) 2005-08-16
AU2004289311A1 (en) 2005-05-26
WO2005046607A2 (en) 2005-05-26
RU2006120491A (ru) 2007-12-20
JP2007524657A (ja) 2007-08-30
IS8496A (is) 2006-06-02
EP1689352A2 (en) 2006-08-16
WO2005046607A3 (en) 2012-12-20
AR046841A1 (es) 2005-12-28
NO20062358L (no) 2006-07-12
IL175611A0 (en) 2008-04-13
CA2545423A1 (en) 2005-05-26
KR20060118514A (ko) 2006-11-23

Similar Documents

Publication Publication Date Title
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
ATE408601T1 (de) Fredericamycin-derivate
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
DE602004024909D1 (de) Platinkomplexe zur behandlung von tumoren
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
BR0312456A (pt) Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
ATE531688T1 (de) Verbindungen zur modulation des rage-rezeptors
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]